243 related articles for article (PubMed ID: 22075999)
21. Factors influencing clinical outcomes of acute ischemic stroke treated with intravenous recombinant tissue plasminogen activator.
Huang YH; Zhuo ST; Chen YF; Li MM; Lin YY; Yang ML; Chen ZJ; Cai RW
Chin Med J (Engl); 2013; 126(24):4685-90. PubMed ID: 24342312
[TBL] [Abstract][Full Text] [Related]
22. Gender and thrombolysis therapy in acute ischemic stroke patients with incidence of obesity.
Blum B; Penwell A; Wormack L; Walker B; Lari S; Nathaniel TI
Neurol Sci; 2019 Sep; 40(9):1829-1839. PubMed ID: 31049791
[TBL] [Abstract][Full Text] [Related]
23. Clinical Risk Factors in Thrombolysis therapy: Telestroke Versus Nontelestroke.
Nathaniel TI; Gainey J; Blum B; Montgomery C; Ervin L; Madeline L
J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):2524-2533. PubMed ID: 29859864
[TBL] [Abstract][Full Text] [Related]
24. Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke.
Brown DL; Johnston KC; Wagner DP; Haley EC
Stroke; 2004 Jan; 35(1):147-50. PubMed ID: 14657446
[TBL] [Abstract][Full Text] [Related]
25. Post rtPA CT brain may not be mandatory in all stroke patients when resources are limited.
Dharmasaroja PA; Muengtaweepongsa S; Dharmasaroja P
Clin Neurol Neurosurg; 2013 Mar; 115(3):285-8. PubMed ID: 22749008
[TBL] [Abstract][Full Text] [Related]
26. Time trends in systemic thrombolysis in a large hospital-based stroke registry.
Singer OC; Hamann GF; Misselwitz B; Steinmetz H; Foerch C;
Cerebrovasc Dis; 2012; 33(4):316-21. PubMed ID: 22343969
[TBL] [Abstract][Full Text] [Related]
27. Pharmacist Impact on Ischemic Stroke Care in the Emergency Department.
Gosser RA; Arndt RF; Schaafsma K; Dang CH
J Emerg Med; 2016 Jan; 50(1):187-93. PubMed ID: 26412104
[TBL] [Abstract][Full Text] [Related]
28. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: way to endeavor.
Huang P; Chen CH; Yang YH; Lin RT; Lin FC; Liu CK
Cerebrovasc Dis; 2006; 22(5-6):423-8. PubMed ID: 16912476
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of blood pressure profiles as predictors of long-term outcome after acute ischemic stroke.
Yong M; Diener HC; Kaste M; Mau J
Stroke; 2005 Dec; 36(12):2619-25. PubMed ID: 16254220
[TBL] [Abstract][Full Text] [Related]
30. Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: An international multicenter 2 × 2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment.
Huang Y; Sharma VK; Robinson T; Lindley RI; Chen X; Kim JS; Lavados P; Olavarría V; Arima H; Fuentes S; Nguyen HT; Lee TH; Parsons MW; Levi C; Demchuk AM; Bath PM; Broderick JP; Donnan GA; Martins S; Pontes-Neto OM; Silva F; Pandian J; Ricci S; Stapf C; Woodward M; Wang J; Chalmers J; Anderson CS;
Int J Stroke; 2015 Jul; 10(5):778-88. PubMed ID: 25832995
[TBL] [Abstract][Full Text] [Related]
31. Serum neuron specific enolase level as a predictor of prognosis in acute ischemic stroke patients after intravenous thrombolysis.
Lu K; Xu X; Cui S; Wang F; Zhang B; Zhao Y
J Neurol Sci; 2015 Dec; 359(1-2):202-6. PubMed ID: 26671113
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of Thai patients with acute ischemic stroke after intravenous thrombolysis.
Dharmasaroja PA; Dharmasaroja P; Muengtaweepongsa S
J Neurol Sci; 2011 Jan; 300(1-2):74-7. PubMed ID: 20937509
[TBL] [Abstract][Full Text] [Related]
33. Defining mild stroke: outcomes analysis of treated and untreated mild stroke patients.
Spokoyny I; Raman R; Ernstrom K; Khatri P; Meyer DM; Hemmen TM; Meyer BC
J Stroke Cerebrovasc Dis; 2015 Jun; 24(6):1276-81. PubMed ID: 25906938
[TBL] [Abstract][Full Text] [Related]
34. The rtPA increases MMP-9 activity in serum during ischaemic stroke.
Gołąb P; Boguszewska-Czubara A; Kiełbus M; Kurzepa J
Neurol Neurochir Pol; 2014; 48(5):309-14. PubMed ID: 25440008
[TBL] [Abstract][Full Text] [Related]
35. Effects of edaravone on early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator.
Wada T; Yasunaga H; Inokuchi R; Horiguchi H; Fushimi K; Matsubara T; Nakajima S; Yahagi N
J Neurol Sci; 2014 Oct; 345(1-2):106-11. PubMed ID: 25085762
[TBL] [Abstract][Full Text] [Related]
36. Thrombolytic therapy for acute stroke in the elderly: an emergent condition in developing countries.
Martins SC; Friedrich MA; Brondani R; de Almeida AG; de Araújo MD; Chaves ML; Berger JR; Massaro AR
J Stroke Cerebrovasc Dis; 2011; 20(5):459-64. PubMed ID: 20813552
[TBL] [Abstract][Full Text] [Related]
37. Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR).
Wang Y; Liao X; Zhao X; Wang DZ; Wang C; Nguyen-Huynh MN; Zhou Y; Liu L; Wang X; Liu G; Li H; Wang Y;
Stroke; 2011 Jun; 42(6):1658-64. PubMed ID: 21512182
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of Patients Requiring Blood Pressure Control Before Thrombolysis with tPA for Acute Ischemic Stroke.
Darger B; Gonzales N; Banuelos RC; Peng H; Radecki RP; Doshi PB
West J Emerg Med; 2015 Dec; 16(7):1002-6. PubMed ID: 26759644
[TBL] [Abstract][Full Text] [Related]
39. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study.
Kleindorfer D; Kissela B; Schneider A; Woo D; Khoury J; Miller R; Alwell K; Gebel J; Szaflarski J; Pancioli A; Jauch E; Moomaw C; Shukla R; Broderick JP;
Stroke; 2004 Feb; 35(2):e27-9. PubMed ID: 14739423
[TBL] [Abstract][Full Text] [Related]
40. Impact of the extended thrombolysis time window on the proportion of recombinant tissue-type plasminogen activator-treated stroke patients and on door-to-needle time.
Minnerup J; Wersching H; Ringelstein EB; Schilling M; Schäbitz WR; Wellmann J; Berger K
Stroke; 2011 Oct; 42(10):2838-43. PubMed ID: 21852612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
